A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder

Eric Hollander, Alicia Kaplan, Stephen M. Stahl

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are currently the first-line pharmacological agents in treating obsessive-compulsive disorder (OCD). Appropriate treatment for OCD also involves cognitive behavioural therapy (CBT), including exposure and response prevention. As there is a time delay in seeing full therapeutic response, and not all patients tolerate SSRIs, there remains an unmet need for additional treatment approaches in OCD. In addition, most responders report only a partial reduction in symptoms. Clonazepam has demonstrated effectiveness in several preliminary reports in treating OCD. Twenty-seven patients with OCD were entered into a 10-week, double-blind, parallel design trial of clonazepam vs. placebo. Overall, only 3 out of 25 patients who had ≥ 1 rating on clonazepam/placebo were judged to be treatment responders, by scoring a 1 (very much improved) or 2 (much improved) on the CGI improvement scale. Responders included 2 of 9 in the placebo group and 1 of 16 in the clonazepam group. No significant difference was found between clonazepam and placebo groups on responder/non responder status (X2 = 1.39, df = 1,24, p=0.238), nor on change in YBOCS, HAM-A, HAM-D or NIMH scales from beginning to last evaluation carried forward. These findings suggest that clonazepam is not effective as monotherapy in treating OCD. Its effectiveness in specific subgroups of OCD patients with co-morbid anxiety disorders or as an augmentation strategy added to SSRIs remains to be determined.

Original languageEnglish (US)
Pages (from-to)30-34
Number of pages5
JournalWorld Journal of Biological Psychiatry
Volume4
Issue number1
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Clonazepam
Obsessive-Compulsive Disorder
Placebos
Serotonin Uptake Inhibitors
National Institute of Mental Health (U.S.)
Cognitive Therapy
Therapeutics
Anxiety Disorders
Pharmacology

Keywords

  • benzodiazepine
  • clonazepam
  • obsessive-compulsive disorder
  • serotonin

ASJC Scopus subject areas

  • Biological Psychiatry
  • Psychiatry and Mental health

Cite this

A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. / Hollander, Eric; Kaplan, Alicia; Stahl, Stephen M.

In: World Journal of Biological Psychiatry, Vol. 4, No. 1, 2003, p. 30-34.

Research output: Contribution to journalArticle

@article{e24104d9be1e4f04bfa778ca414aa678,
title = "A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder",
abstract = "Selective serotonin reuptake inhibitors (SSRIs) are currently the first-line pharmacological agents in treating obsessive-compulsive disorder (OCD). Appropriate treatment for OCD also involves cognitive behavioural therapy (CBT), including exposure and response prevention. As there is a time delay in seeing full therapeutic response, and not all patients tolerate SSRIs, there remains an unmet need for additional treatment approaches in OCD. In addition, most responders report only a partial reduction in symptoms. Clonazepam has demonstrated effectiveness in several preliminary reports in treating OCD. Twenty-seven patients with OCD were entered into a 10-week, double-blind, parallel design trial of clonazepam vs. placebo. Overall, only 3 out of 25 patients who had ≥ 1 rating on clonazepam/placebo were judged to be treatment responders, by scoring a 1 (very much improved) or 2 (much improved) on the CGI improvement scale. Responders included 2 of 9 in the placebo group and 1 of 16 in the clonazepam group. No significant difference was found between clonazepam and placebo groups on responder/non responder status (X2 = 1.39, df = 1,24, p=0.238), nor on change in YBOCS, HAM-A, HAM-D or NIMH scales from beginning to last evaluation carried forward. These findings suggest that clonazepam is not effective as monotherapy in treating OCD. Its effectiveness in specific subgroups of OCD patients with co-morbid anxiety disorders or as an augmentation strategy added to SSRIs remains to be determined.",
keywords = "benzodiazepine, clonazepam, obsessive-compulsive disorder, serotonin",
author = "Eric Hollander and Alicia Kaplan and Stahl, {Stephen M.}",
year = "2003",
doi = "10.3109/15622970309167908",
language = "English (US)",
volume = "4",
pages = "30--34",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder

AU - Hollander, Eric

AU - Kaplan, Alicia

AU - Stahl, Stephen M.

PY - 2003

Y1 - 2003

N2 - Selective serotonin reuptake inhibitors (SSRIs) are currently the first-line pharmacological agents in treating obsessive-compulsive disorder (OCD). Appropriate treatment for OCD also involves cognitive behavioural therapy (CBT), including exposure and response prevention. As there is a time delay in seeing full therapeutic response, and not all patients tolerate SSRIs, there remains an unmet need for additional treatment approaches in OCD. In addition, most responders report only a partial reduction in symptoms. Clonazepam has demonstrated effectiveness in several preliminary reports in treating OCD. Twenty-seven patients with OCD were entered into a 10-week, double-blind, parallel design trial of clonazepam vs. placebo. Overall, only 3 out of 25 patients who had ≥ 1 rating on clonazepam/placebo were judged to be treatment responders, by scoring a 1 (very much improved) or 2 (much improved) on the CGI improvement scale. Responders included 2 of 9 in the placebo group and 1 of 16 in the clonazepam group. No significant difference was found between clonazepam and placebo groups on responder/non responder status (X2 = 1.39, df = 1,24, p=0.238), nor on change in YBOCS, HAM-A, HAM-D or NIMH scales from beginning to last evaluation carried forward. These findings suggest that clonazepam is not effective as monotherapy in treating OCD. Its effectiveness in specific subgroups of OCD patients with co-morbid anxiety disorders or as an augmentation strategy added to SSRIs remains to be determined.

AB - Selective serotonin reuptake inhibitors (SSRIs) are currently the first-line pharmacological agents in treating obsessive-compulsive disorder (OCD). Appropriate treatment for OCD also involves cognitive behavioural therapy (CBT), including exposure and response prevention. As there is a time delay in seeing full therapeutic response, and not all patients tolerate SSRIs, there remains an unmet need for additional treatment approaches in OCD. In addition, most responders report only a partial reduction in symptoms. Clonazepam has demonstrated effectiveness in several preliminary reports in treating OCD. Twenty-seven patients with OCD were entered into a 10-week, double-blind, parallel design trial of clonazepam vs. placebo. Overall, only 3 out of 25 patients who had ≥ 1 rating on clonazepam/placebo were judged to be treatment responders, by scoring a 1 (very much improved) or 2 (much improved) on the CGI improvement scale. Responders included 2 of 9 in the placebo group and 1 of 16 in the clonazepam group. No significant difference was found between clonazepam and placebo groups on responder/non responder status (X2 = 1.39, df = 1,24, p=0.238), nor on change in YBOCS, HAM-A, HAM-D or NIMH scales from beginning to last evaluation carried forward. These findings suggest that clonazepam is not effective as monotherapy in treating OCD. Its effectiveness in specific subgroups of OCD patients with co-morbid anxiety disorders or as an augmentation strategy added to SSRIs remains to be determined.

KW - benzodiazepine

KW - clonazepam

KW - obsessive-compulsive disorder

KW - serotonin

UR - http://www.scopus.com/inward/record.url?scp=0037494710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037494710&partnerID=8YFLogxK

U2 - 10.3109/15622970309167908

DO - 10.3109/15622970309167908

M3 - Article

C2 - 12582975

AN - SCOPUS:0037494710

VL - 4

SP - 30

EP - 34

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 1

ER -